For in vitro diagnostic use. Others Elecsys Troponin T hs IVD Elecsys® Troponin T hs CPS_000530 09744754190 Troponin T hs Elecsys E2G 100 V2.1 Elecsys Troponin T hs 07613336217634 Reagents, kits 100 tests cobas e 402/801 undefined 08469873190 Troponin T hs Elecsys E2G 300 V2 Elecsys Troponin T hs 07613336158968 Reagents, kits 300 tests cobas e 402/801 true 09315322190 Troponin T hs Elecsys cobas e 200 V2.1 Elecsys Troponin T hs 07613336191583 Reagents, kits 200 tests cobas e 411/601/602 true 08469717190 Troponin T hs Elecsys cobas e 200 V2 Elecsys Troponin T hs 07613336158920 Reagents, kits 200 tests cobas e 411/601/602 true 09315357190 Troponin T hs Elecsys E2G 300 V2.1 Elecsys Troponin T hs 07613336191606 Reagents, kits 300 tests cobas e 402/801 true 08469873500 Elecsys Troponin T hs en 7 FF0000000596B30E FF0000000416230E 08469873190 2497 cobas e 801 9494 cobas e 402 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the in vitro quantitative determination of cardiac troponin T in human serum and plasma. This assay can be used as an aid in the differential diagnosis of acute coronary syndrome to identify necrosis, e.g. acute myocardial infarction. The test is further indicated for the risk stratification of patients presenting with acute coronary syndrome and for cardiac risk in patients with chronic renal failure. The test may also be useful for the selection of more intensive therapy and intervention in patients with elevated levels of cardiac troponin T.The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers. en 09315322500 Elecsys Troponin T hs en 3 FF000000063FCE0E FF000000047CE20E 09315322190 618 cobas e 411 2325 cobas e 602 619 cobas e 601 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the in vitro quantitative determination of cardiac troponin T in human serum and plasma. This assay can be used as an aid in the differential diagnosis of acute coronary syndrome to identify necrosis e.g. acute myocardial infarction (AMI), and as an aid for early discharge and outpatient management for patients suspected of acute coronary syndrome (ACS). The test is further indicated for the risk stratification of patients presenting with acute coronary syndrome and for cardiac risk in patients with chronic renal failure. The test may also be useful for the selection of more intensive therapy and intervention in patients with elevated levels of cardiac troponin T (cTnT).In addition, this test can be used in the context of non‑cardiac surgeries to predict pre‑operatively the perioperative risk of major adverse cardiac events and in diagnosis of perioperative myocardial infarction (PMI) and myocardial injuries after non-cardiac surgeries (MINS).The cTnT‑hs values may also be used, in conjunction with clinical and diagnostics findings, to aid in stratifying the long-term risk of cardiovascular death, myocardial infarction, coronary revascularization, heart failure or ischemic stroke, and all-cause mortality in asymptomatic individuals.The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers. en 08469717500 Elecsys Troponin T hs en 4 FF000000057A0A0E FF0000000356680E 08469717190 618 cobas e 411 2325 cobas e 602 619 cobas e 601 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the in vitro quantitative determination of cardiac troponin T in human serum and plasma. This assay can be used as an aid in the differential diagnosis of acute coronary syndrome to identify necrosis, e.g. acute myocardial infarction. The test is further indicated for the risk stratification of patients presenting with acute coronary syndrome and for cardiac risk in patients with chronic renal failure. The test may also be useful for the selection of more intensive therapy and intervention in patients with elevated levels of cardiac troponin T.The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers. en 09315357500 Elecsys Troponin T hs en 4 FF0000000660900E FF000000047CE40E 09315357190 2497 cobas e 801 9494 cobas e 402 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the in vitro quantitative determination of cardiac troponin T in human serum and plasma. This assay can be used as an aid in the differential diagnosis of acute coronary syndrome to identify necrosis, e.g. acute myocardial infarction (AMI), and as an aid for early discharge and outpatient management for patients suspected of acute coronary syndrome (ACS). The test is further indicated for the risk stratification of patients presenting with acute coronary syndrome and for cardiac risk in patients with chronic renal failure. The test may also be useful for the selection of more intensive therapy and intervention in patients with elevated levels of cardiac troponin T (cTnT).In addition, this test can be used in the context of non‑cardiac surgeries to predict pre‑operatively the perioperative risk of major adverse cardiac events and in diagnosis of perioperative myocardial infarction (PMI) and myocardial injuries after non-cardiac surgeries (MINS).The cTnT‑hs values may also be used, in conjunction with clinical and diagnostics findings, to aid in stratifying the long-term risk of cardiovascular death, myocardial infarction, coronary revascularization, heart failure or ischemic stroke, and all-cause mortality in asymptomatic individuals.The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers. en